Idorsia Expands Daridorexant Data with Pediatric, Real-World Insomnia Studies

  • Idorsia presents first pediatric insomnia data for daridorexant at Sleep Europe 2026, marking the only clinical study of a dual orexin receptor antagonist in children.
  • Real-world evidence studies show daridorexant's impact on sleep outcomes, daytime functioning, and work productivity in routine clinical practice.
  • Six investigator-initiated studies explore daridorexant in menopausal women, epilepsy patients, and those with major depressive disorder.
  • Phase 3 analysis examines daridorexant's efficacy in adults with insomnia and short sleep duration.

Idorsia's presentation of new daridorexant data at Sleep Europe 2026 underscores the company's push to expand the drug's clinical evidence beyond adult insomnia. The focus on pediatric patients, real-world outcomes, and specialized populations like menopausal women and epilepsy patients highlights a strategic effort to carve out niche markets. The broader industry trend toward dual orexin receptor antagonists as safer alternatives to traditional hypnotics positions Idorsia to capitalize on growing demand for non-sedating sleep solutions.

Pediatric Market Expansion
Whether Idorsia can leverage these pediatric results to gain regulatory approval and enter a currently underserved market.
Real-World Adoption
How the growing body of real-world evidence will influence prescribing patterns and reimbursement policies across different healthcare systems.
Competitive Positioning
The pace at which Idorsia can differentiate daridorexant from traditional sedative-hypnotics in the evolving insomnia treatment landscape.